AstraZeneca launches health-tech business ‘Evinova’
Evinova will operate as a separate health-tech business within AstraZeneca
Evinova will operate as a separate health-tech business within AstraZeneca
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The company has raised US$4.5 million in funding for its AI operating system
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
European operations' revenue grew 58.4% to Rs 599.7 crore
The collaboration brings a seamless digital experience to more formulators worldwide
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Total transaction value of the divestment is Rs. 3,660 million
Subscribe To Our Newsletter & Stay Updated